ASCO: For chemo's nausea, olanzapine beats metoclopramide

ASCO: for chemo's nausea, olanzapine beats metoclopramide

(HealthDay) -- For patients receiving highly emetogenic chemotherapy who experience breakthrough chemotherapy-induced nausea and vomiting, treatment with olanzapine (Zyprexa) is significantly better than treatment with metoclopramide, according to a phase III study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Rudolph M. Navari, M.D., Ph.D., from the Indiana University School of Medicine South Bend, and colleagues conducted a randomized double-blind trial in chemotherapy-naive patients receiving highly emetogenic chemotherapy. Patients who developed breakthrough emesis or nausea, despite receiving guideline-recommended prophylactic treatment for chemotherapy-induced , were randomly allocated to receive (42 patients) or metoclopramide (38 patients) orally for three days. Patients were monitored for 72 hours after treatment.

During the 72-hour observation period, the researchers found that 71 percent of patients receiving olanzapine and 32 percent receiving metoclopramide had no emesis (P < 0.01). During the observation period, the proportion of patients without nausea was 67 percent of those treated with olanzapine versus 24 percent of those treated with (P < 0.01). The investigators noted no grade 3 or 4 toxicities.

"This study suggests that olanzapine will be very useful in these patients who feel very sick and sometimes come to the clinic, hospital, or emergency room. As a result, patients will feel better," Navari said in a statement.

More information: Abstract
More Information

add to favorites email to friend print save as pdf

Related Stories

Chemo-induced nausea remains big problem, study says

Jun 02, 2011

A large, phase III study of four commonly used drug regimens to treat chemotherapy-induced nausea concluded that while two regimens were better at managing patients’ queasiness, none were totally effective – prompting ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

10 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

16 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

16 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments